Literature DB >> 17367261

Tenofovir-induced kidney injury.

Michael D Gitman1, David Hirschwerk, Cindy H Baskin, Pravin C Singhal.   

Abstract

Tenofovir disoproxil fumarate is a nucleotide reverse transcriptase inhibitor with activity against both HIV and the hepatitis B virus. It has had minimal nephrotoxic effects in early clinical trials, but as clinical use has widened, case reports describing tenofovir-induced renal tubular damage, Fanconi's syndrome and diabetes insipidus have been described. The authors review the pharmacokinetics, mechanism of action and clinical uses of tenofovir disoproxil fumarate. The large clinical trials, as well as the case reports of tenofovir-induced kidney injury, are also reviewed. The potential mechanism of renal damage is discussed and recommendations for evaluation and treatment of tenofovir-induced kidney injury are given.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17367261     DOI: 10.1517/14740338.6.2.155

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  14 in total

1.  Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B.

Authors:  Andrés Duarte-Rojo; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

Review 2.  Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention.

Authors:  Atefeh Jafari; Hossein Khalili; Simin Dashti-Khavidaki
Journal:  Eur J Clin Pharmacol       Date:  2014-06-25       Impact factor: 2.953

Review 3.  Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients.

Authors:  Zygimantas C Alsauskas; Raj Kiran Medapalli; Michael J Ross
Journal:  Expert Opin Pharmacother       Date:  2011-01-21       Impact factor: 3.889

4.  Tenofovir Disoproxil Fumarate Is a New Substrate of ATP-Binding Cassette Subfamily C Member 11.

Authors:  Wisith Tun-Yhong; Chatchai Chinpaisal; Perayot Pamonsinlapatham; Sindchai Kaewkitichai
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

5.  THE RISKS OF CONCURRENT TREATMENT WITH TENOFOVIR AND AMINOGLYCOSIDES IN PATIENTS WITH HIV-ASSOCIATED TUBERCULOSIS.

Authors:  Chris Kenyon; Nicci Wearne; Rosie Burton; Graeme Meintjes
Journal:  South Afr J HIV Med       Date:  2011       Impact factor: 2.744

6.  Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.

Authors:  Koen K A Van Rompay; Lucie Durand-Gasselin; Laurie L Brignolo; Adrian S Ray; Kristina Abel; Tomas Cihlar; Abigail Spinner; Christopher Jerome; Joseph Moore; Brian P Kearney; Marta L Marthas; Hans Reiser; Norbert Bischofberger
Journal:  Antimicrob Agents Chemother       Date:  2008-06-23       Impact factor: 5.191

7.  Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.

Authors:  Leah Tong; Truc K Phan; Kelly L Robinson; Darius Babusis; Robert Strab; Siddhartha Bhoopathy; Ismael J Hidalgo; Gerald R Rhodes; Adrian S Ray
Journal:  Antimicrob Agents Chemother       Date:  2007-07-30       Impact factor: 5.191

Review 8.  Antiviral drugs for viruses other than human immunodeficiency virus.

Authors:  Raymund R Razonable
Journal:  Mayo Clin Proc       Date:  2011-10       Impact factor: 7.616

Review 9.  Differentiating HIV-associated nephropathy from antiretroviral drug-induced nephropathy: a clinical challenge.

Authors:  Neelja Kumar; Mark A Perazella
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.495

10.  Tenofovir and its potential in the treatment of hepatitis B virus.

Authors:  Laura Reynaud; Maria Aurora Carleo; Maria Talamo; Guglielmo Borgia
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.